Standout Papers

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein 2008 2026 2014 2020 4.6k
  1. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (2008)
    Paul M. Ridker, Eleanor Danielson et al. New England Journal of Medicine
  2. Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein (2009)
    Paul M. Ridker, Eleanor Danielson et al. Obstetrical & Gynecological Survey
  3. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial (2009)
    Paul M. Ridker, Eleanor Danielson et al. The Lancet
  4. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial (2012)
    Paul M. Ridker, Aruna D. Pradhan et al. The Lancet
  5. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism (2009)
    Robert J. Glynn, Eleanor Danielson et al. New England Journal of Medicine
  6. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) (2018)
    Paul M. Ridker, Peter Libby et al. European Heart Journal
  7. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease (2011)
    JoAnn E. Manson, Shari S. Bassuk et al. Contemporary Clinical Trials
  8. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials (2023)
    Paul M. Ridker, Deepak L. Bhatt et al. The Lancet

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 91 standout
Sub-graph 1 of 15

Citing Papers

Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations
2024 Standout
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
2024 Standout
57 intermediate papers

Works of Jean MacFadyen being referenced

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
2023 Standout
Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study
2008
and 17 more

Author Peers

Author Last Decade Papers Cites
Jean MacFadyen 7907 3965 3194 56 14.9k
Francisco Antônio Helfenstein Fonseca 6085 3343 2477 148 11.4k
Olov Wiklund 6099 3307 3550 156 13.1k
Alberto Lorenzatti 5689 2741 2297 25 9.3k
M. John Chapman 8021 3169 5509 133 13.8k
John R. Guyton 6098 2465 3227 164 11.7k
Eleanor Danielson 5522 2773 2206 15 9.8k
Luther T. Clark 8448 7315 7311 99 21.8k
Chris J. Packard 7876 4657 7235 204 18.5k
Stuart M. Cobbe 8907 6389 4608 158 17.7k
Colin Baigent 10882 8741 4631 135 22.1k

All Works

Loading papers...

Rankless by CCL
2026